Abstract
The introduction of highly active antiretroviral therapy (HAART) in the mid1990s for the treatment of human immunodeficiency virus (HIV) infection was associated with a rapid reduction in the incidence of most AIDS-defining events. Although early studies suggested that HAART appeared to have a less dramatic effect on the incidence of AIDS-related lymphomas, particularly non-Hodgkin lymphoma (NHL), than on the incidence of other AIDS-related events [1, 2], subsequent studies confirmed that the incidence of these events had also decreased [3-6]. In the CASCADE (Concerted Action of SeroConversion to AIDS and Death in Europe) Collaboration, the incidence of NHL decreased by 75% from the period before 1997 to 1999-2002 [3]. Among participants in the Swiss HIV Cohort Study [4], the incidence of NHL decreased from 13.6 cases/1000 person-years during the period from 1993 to 1995 to
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
